Cargando…

Usefulness of anti-vascular endothelial growth factor combined with dexamethasone implant for retinal vein occlusion

Detalles Bibliográficos
Autor principal:	Kim, Moosang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072552/ https://www.ncbi.nlm.nih.gov/pubmed/27789939 http://dx.doi.org/10.2147/CIA.S121535

Ejemplares similares

Dexamethasone implant in retinal vein occlusions
por: Han, Sang Beom, et al.
Publicado: (2016)

Anti-vascular endothelial growth factor treatment in diabetic macular edema
por: Kim, Moosang
Publicado: (2016)

Commentary on “Intravitreal dexamethasone implant for management of treatment-naïve retinal vein occlusion”
por: Bansal, Mayank
Publicado: (2018)

Clinical Use of Dexamethasone Implants in Resistant Macular Edema Secondary to Branch Retinal Vascular Occlusion Compared with Intravitreal Anti-Vascular Endothelial Growth Factor
por: Eris, Erdem, et al.
Publicado: (2019)

Therapeutic effect of dexamethasone implant in retinal vein occlusions resistant to anti-VEGF therapy
por: Wallsh, Josh, et al.
Publicado: (2016)

Improving blood flow in occluded veins to reduce anti-vascular endothelial growth factor injections for branch retinal vein occlusion
por: Maeno, Takatoshi, et al.
Publicado: (2023)

Effects of Dexamethasone Implant on Multifocal Electroretinography in Central Retinal Vein Occlusion
por: Bulut, Muhammed Nurullah, et al.
Publicado: (2018)

Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy
por: Shchuko, Andrey G, et al.
Publicado: (2015)

Anti-vascular endothelial growth factor agent reduces inflammation in macular edema with central retinal vein occlusion
por: Mashima, Asako, et al.
Publicado: (2019)

Intravitreal dexamethasone implant for central retinal vein occlusion without macular edema
por: Choi, Eun Young, et al.
Publicado: (2019)

Evaluating the One-Year Efficacy of Combined Anti-VEGF and Dexamethasone Implant Treatment for Macular Edema in Retinal Vein Occlusions
por: Ren, Fengmei, et al.
Publicado: (2023)

Impact of Intravitreal Dexamethasone Implant on Vessel Diameters in Patients with Retinal Vein Occlusion
por: Yilmaz Tugan, Busra, et al.
Publicado: (2019)

Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors
por: Spooner, Kimberly, et al.
Publicado: (2019)

Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser
por: Gale, Richard, et al.
Publicado: (2021)

Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema
por: Kiss, Szilárd, et al.
Publicado: (2014)

A Meta-Analysis of Anti-Vascular Endothelial Growth Factor Remedy for Macular Edema Secondary to Central Retinal Vein Occlusion
por: Huang, Peirong, et al.
Publicado: (2013)

Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor
por: Nixon, Donald R, et al.
Publicado: (2021)

Anti-Vascular Endothelial Growth Factor Therapy with or Without Initial Steroid Therapy for Macular Edema in Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2023)

Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion
por: Modi, Yasha S., et al.
Publicado: (2023)

Outcomes of Combination Therapy using Aflibercept and Dexamethasone Intravitreal Implant versus Dexamethasone Monotherapy for Macular Edema Secondary to Retinal Vein Occlusion
por: Harb, Walid, et al.
Publicado: (2021)

Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex®) in its treatment
por: Garweg, Justus G., et al.
Publicado: (2016)

Dexamethasone intravitreous implant vs bevacizumab for central retinal vein occlusion‐related macular oedema: A prospective randomized comparison—Comment
por: Wen, Dejia, et al.
Publicado: (2019)

Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients: Corneal endothelium after dexamethasone implant injection
por: Güler, Hatice Ayhan, et al.
Publicado: (2018)

Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series
por: Singer, Michael A, et al.
Publicado: (2016)

Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex(®)) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
por: Chan, Annie, et al.
Publicado: (2011)

Dexamethasone Implant (Ozurdex) in a Case with Unilateral Simultaneous Central Retinal Vein and Branch Retinal Artery Occlusion
por: Ozturk, Taylan, et al.
Publicado: (2015)

Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion
por: Liang, Xuemei, et al.
Publicado: (2022)

Efficacy and Safety in Retinal Vein Occlusion Treated with at Least Three Consecutive Intravitreal Dexamethasone Implants
por: Proença Pina, Julia, et al.
Publicado: (2016)

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
por: Nghiem-Buffet, S, et al.
Publicado: (2017)

Epiretinal membrane after branch retinal vein occlusion: Separation after dexamethasone implant injection
por: Alshahrani, Saeed T., et al.
Publicado: (2022)

Reversal of Early Central Retinal Vein Occlusion by Alleviating Optic Nerve Edema with an Intravitreal Dexamethasone Implant
por: Cho, Young Joo, et al.
Publicado: (2014)

Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration
por: Kim, Moosang, et al.
Publicado: (2016)

Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion
por: Hwang, De-Kuang, et al.
Publicado: (2020)

Predictors of Visual Acuity Outcomes after Anti–Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion
por: Sen, Piyali, et al.
Publicado: (2021)

Outcomes of Eyes Lost to Follow-Up in Patients with Central Retinal Vein Occlusion Who are Receiving Anti-Vascular Endothelial Growth Factor Treatment
por: Yang, Kai-Bo, et al.
Publicado: (2021)

Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors – a population-based cohort study
por: Lee, Wan-Ju Annabelle, et al.
Publicado: (2023)

Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion
por: Chung, Yoo-Ri, et al.
Publicado: (2023)

Significant Correlation between Retinal Venous Tortuosity and Aqueous Vascular Endothelial Growth Factor Concentration in Eyes with Central Retinal Vein Occlusion
por: Yasuda, Shunsuke, et al.
Publicado: (2015)

Analyze of factors and prognosis of eyes lost to follow-up in retinal vein occlusive disease patients receiving anti-vascular endothelial growth factor therapy
por: Huang, Xiaoying, et al.
Publicado: (2023)

Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: a meta-analysis
por: Gao, Lixiong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_08v6t18g8sgbs1tkelbnponid1